Hematopoiesis News Volume 4.43 | Nov 5 2013

In Vivo Leukemogenic Potential of an Interleukin-7 Receptor α Chain Mutant in Hematopoietic Stem and Progenitor Cells
Researchers found that ectopic expression of INS alone in hematopoietic stem/progenitor cells caused myeloproliferative disorders, whereas expression of INS in combination with a Notch1 mutant led to the development of much more aggressive T acute lymphoblastic leukemia than with wild-type interleukin-7 receptor α chain. [Blood] Abstract

Thrombopoietin Promotes Non-Homologous End Joining DNA Repair in Hematopoietic Stem Cells through Specific Activation of Erk and NF-κB Pathways and Their Target IEX-1
Scientists showed that thrombopoietin (TPO) specifically triggers Erk and NF-κB pathways in mouse hematopoietic stem and progenitors cells. These pathways are both required for TPO-mediated increase in double-strand break repair. [Blood] Abstract

In Vivo Generation of Decidual Natural Killer Cells from Resident Hematopoietic Progenitors
Scientists identified Natural Killer precursors in decidua and uterus of pregnant mice. These precursors underwent rapid in situ differentiation and large proportions of proliferating immature Natural Killer cells were present in decidua and uterus as early as gestation day 4,5. [Haematologica] Abstract

ZNF16 (HZF1) Promotes Erythropoiesis and Megakaryocytopoiesis via Its Regulation on c-KIT Gene
The authors investigated ZNF16’s effect in erythroid and megakaryocytic differentiation of hematopoietic stem/progenitor cells (HSPCs) and the mechanisms. They observed up-regulation of ZNF16 during erythroid and megakaryocytic differentiation of the CD34+ HSPCs, and demonstrated that ZNF16 promotes erythroid and megakaryocytic differentiation by gain-of-function and loss-of-function experiments. [Biochem J] Abstract

Merging Concepts – Coupling an Agent-Based Model of Hematopoietic Stem Cells with an ODE Model of Granulopoiesis
Investigators propose a combination of an ordinary differential equation (ODE) model of human granulopoiesis and an agent-based model of hematopoietic stem cell organization. [BMC Syst Biol]
Abstract | Full Article

Circulating Hematopoietic Progenitor Cells are Decreased in COPD
Researchers measured circulating levels of endothelial progenitor cells and hematopoietic progenitor cells in subjects with COPD and to determine if progenitor levels correlated with disease severity and the presence of emphysema. [COPD-J Chronic Obstr Pulm Dis] Abstract

CLINICAL RESEARCH

The First Tissue-Engineered Airway Transplantation: 5-Year Follow-Up Results
In 2008, the first transplantation of a tissue-engineered trachea in a human being was done to replace an end-staged left main bronchus with malacia in a 30-year-old woman. Researchers report five year follow-up results. [Lancet] Abstract

The Gene Signature in CCAAT-Enhancer-Binding Protein α Dysfunctional Acute Myeloid Leukemia Predicts Responsiveness to Histone Deacetylase Inhibitors
The authors defined the C/EBPα signature characterized by a set of genes upregulated upon C/EBPα activation. They analyzed expression of the C/EBPα signature in a cohort of 525 acute myeloid leukemia patients and identified a subset of samples characterized by low expression of this signature. [Haematologica] Abstract

Mobilization and Engraftment of Peripheral Blood Stem Cells in Healthy Related Donors >55 Years Old
Researchers analyzed the influence of age on the results of mobilization of peripheral blood stem cells in healthy donors as well as on the engraftment and outcome of hematopoietic stem cell transplantation. [Cytotherapy] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Pharmalink Receives US Orphan Drug Designation for Busulipo™, Its Novel Oncology Product for Bone Marrow Transplantation
Pharmalink AB announced its product Busulipo™, a conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation, has received orphan drug designation from the US Food and Drug Administration. [Pharmalink AB] Press Release

bluebird bio Announces First Patient Transplanted in Phase II/III Starbeam ALD-102 Study for the Treatment of CCALD
bluebird bio, Inc. announced that the first subject in its Phase II/III childhood cerebral adrenoleukodystrophy (CCALD) study, Starbeam has undergone infusion with bluebird bio’s Lenti-D drug product in an autologous hematopoietic stem cell transplantation. [bluebird bio] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis research community.

NEW Adult Stem Cell Transplant Physician (John Theurer Cancer Center)

Postdoctoral Position – Transcriptional Regulation in Normal and Malignant Hematopoiesis (Karolinska Institutet)

Postdoctoral Position – Hematopoietic Stem Cell Biology (St. Jude Children’s Research Hospital)

Postdoctoral Position – Human Pluripotent and Hematopoietic Stem Cell Bioinformatics (Albert Einstein College Medicine)

Translational Clinician-Scientist – Stem Cell Transplantation (Boston Children’s Hospital)

Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

Postdoctoral Position – Cellular and Genetic Therapies for Hemoglobinopathies (Blood Systems Research Institute)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.